Granules India has reported a significant rise in its net profit, posting ₹150.2 crore for the third quarter ended December 2025, marking a 28% jump from ₹117.6 crore recorded a year earlier. The growth highlights the company’s steady execution of its strategic initiatives and solid performance across key markets.
Market Performance
The company’s revenue from operations also saw robust growth, climbing 22% to ₹1,387.9 crore from ₹1,137.7 crore in the same quarter last year. This increase was largely driven by the Finished Dosages (FD) segment, particularly in North America and Europe.
Other business segments contributed as follows:
- Finished Dosages (FD): 76% of total revenue
- Active Pharmaceutical Ingredients (API): 11%
- Pharmaceutical Formulation Intermediates (PFI): 11%
- Peptides/CDMO: 2%
These figures underline Granules India’s balanced portfolio and the growing importance of FD products in its overall earnings mix.
Company Details
Granules India continues to strengthen its footprint in international markets while maintaining a diversified revenue base across multiple pharmaceutical segments. Commenting on the quarterly results, CMD Krishna Prasad Chigurupati said:
“Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives, and we are well-positioned for sustained growth momentum.”
Fund Raising Update
The company also secured shareholder approval on January 22 for its planned capital raise of ₹1,762.50 crore through a mix of preferential convertible warrants and equity shares.
The breakdown of the fund raise is as follows:
- Convertible Warrants: 2.5 crore warrants at ₹585 each, aggregating up to ₹1,462.50 crore, issued on a preferential basis to promoter group and non-promoter investor category.
- Equity Shares: Over 51.28 lakh shares at ₹585 per share, totaling up to ₹300 crore, issued on a preferential basis to various non-promoter investors.
This move is expected to support the company’s growth initiatives and strengthen its financial position.
Summary
Granules India’s Q3 results demonstrate a healthy earnings growth and resilient performance across its pharmaceutical segments. With net profit rising 28% to ₹150.2 crore and revenue up 22% to ₹1,387.9 crore, the company shows strong execution and strategic growth, particularly in the FD segment across North America and Europe. The recent approval for a ₹1,762.50 crore fund raise further underlines its ambitions to expand operations and maintain its growth momentum.
Source: The Hindu
Easy & quick
Leave A Comment?